Table 5 Univariate and multivariate analyses of long-term availability of CVP.
Variable | Factor | Number of patients | Availability at six months | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|---|
HR | 95% CI | p value | HR | 95% CI | p value | ||||
Gender | Female | 159 | 91.7% | 1 | Reference | 0.78 | 1 | Reference | 0.62 |
Male | 149 | 91.1% | 1.13 | 0.48–2.66 | 1.25 | 0.52–2.96 | |||
Age |  | 308 |  | 1.01 | 0.97–1.05 | 0.85 |  |  |  |
Primary disease | Benign | 36 | 76.3% | 1 | Reference | 0.003 | 1 | Reference | 0.006 |
Malignant | 272 | 93.1% | 0.24 | 0.10–0.63 |  | 0.24 | 0.09–0.67 | ||
Puncture site | Internal jugular | 217 | 93.3% | 1 | Reference | Â | 1 | Reference | Â |
Subclavian | 86 | 87.3% | 1.64 | 0.67–4.02 | 0.28 | 0.92 | 0.34–2.47 | 0.87 | |
Others | 5 | 80.0% | 6.00 | 0.76–47.1 | 0.09 | 1.23 | 0.13–12.0 | 0.86 | |
Port device | Bard X-Port isp | 101 | 84.6% | 1 | Reference | Â | 1 | Reference | Â |
Orphis CV Kit Neo | 176 | 95.9% | 0.28 | 0.10–0.73 | 0.009 | 0.27 | 0.09–0.79 | 0.02 | |
Others | 31 | 90.0% | 0.53 | 0.12–2.34 | 0.40 | 0.49 | 0.11–2.26 | 0.36 | |
